Lisata gets new patent for certepetide in pancreatic cancer treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Lisata gets new patent for certepetide in pancreatic cancer treatment

Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors

October 8, 2026 8:00 AM EDT

LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (Lisata or the Company), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041.

The newly issued patent, titled Methods for Treating Pancreatic Cancer and Other Solid Tumors, expands Lisatas intellectual property protection for certepetide. The patent covers administering the Companys proprietary cyclic peptide in combination with at least one... More